Overall, the data support our development rationale and indicate that GT-00AxIL15 has great potential as a next-generation tumor-targeted IL-15-based immunocytokine both as monotherapy and as combination partner for other cancer therapeutics in a broad range of solid tumor indications. This evidence concerns the gene IL15 and neoplasm.